Prentiss Smith & Co. Inc. Invests $3.92 Million in Qiagen (NYSE:QGEN)

Prentiss Smith & Co. Inc. purchased a new stake in shares of Qiagen (NYSE:QGEN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 85,986 shares of the company's stock, valued at approximately $3,918,000. Qiagen accounts for approximately 2.5% of Prentiss Smith & Co. Inc.'s investment portfolio, making the stock its 16th largest position.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company's stock worth $26,000 after acquiring an additional 500 shares during the period. Riverview Trust Co bought a new position in shares of Qiagen in the first quarter worth about $28,000. Toronto Dominion Bank bought a new position in shares of Qiagen in the second quarter worth about $27,000. Park Place Capital Corp purchased a new stake in shares of Qiagen in the first quarter worth about $36,000. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock worth $39,000 after buying an additional 243 shares in the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Trading Down 2.0 %

QGEN stock traded down $0.88 during midday trading on Monday, reaching $42.12. 588,995 shares of the company traded hands, compared to its average volume of 1,191,143. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The business has a 50 day moving average of $45.03 and a 200-day moving average of $43.55. The firm has a market capitalization of $9.61 billion, a price-to-earnings ratio of 28.27, a P/E/G ratio of 3.36 and a beta of 0.39.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The business had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. During the same period in the prior year, the business posted $0.53 earnings per share. The company's quarterly revenue was down .2% compared to the same quarter last year. As a group, sell-side analysts expect that Qiagen will post 2.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on QGEN shares. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. Wolfe Research upgraded Qiagen from a "peer perform" rating to an "outperform" rating and set a $50.00 target price on the stock in a research report on Thursday, June 27th. Hsbc Global Res upgraded Qiagen to a "hold" rating in a research report on Thursday. Finally, HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $50.12.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.